Cargando…
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers
Currently, no disease modifying therapies (DMTs) have been approved for use in dementia with Lewy bodies (DLB). Clinical trials face difficulties due to the clinical and neuropathological heterogeneity of the condition with a diverse array of neuropathogenic mechanisms contributing to the clinical p...
Autores principales: | Gibson, Lucy L., Abdelnour, Carla, Chong, Joyce, Ballard, Clive, Aarsland, Dag |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328538/ https://www.ncbi.nlm.nih.gov/pubmed/37387459 http://dx.doi.org/10.1097/WCO.0000000000001173 |
Ejemplares similares
-
Defining the presymptomatic phase of frontotemporal dementia
por: Russell, Lucy L., et al.
Publicado: (2023) -
Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022
por: Abdelnour, Carla, et al.
Publicado: (2023) -
Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study
por: Stubendorff, Kajsa, et al.
Publicado: (2014) -
Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias
por: Howlett, David R., et al.
Publicado: (2014) -
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes
por: Tan, Rachel H., et al.
Publicado: (2017)